Mesenchymal Stem Cell Trials for Pulmonary Diseases
Mesenchymal Stem Cell Trials for Pulmonary Diseases
复制标题
DOI：
10.1002/jcb.24783
复制
发表时间：
2014-06-01
影响因子：
4
通讯作者：
Rocco, Patricia R. M.
中科院分区：
文献类型：
--
作者：
Antunes, Mariana A.;Laffey, John G.;Rocco, Patricia R. M.
所有成人组织，包括肺，都有一定的自我修复能力，或通过这些器官内干细胞的复制和分化而再生。虽然肺驻留干细胞是肺部疾病的明显候选细胞疗法，但我们对这些细胞的生物学知识存在局限性。相反，外源性细胞，特别是间充质干细胞/基质细胞（MSC），对肺部疾病的治疗潜力有相当大的兴趣。骨髓源性间充质干细胞是目前研究最多的用于治疗这些疾病的细胞疗法。临床前研究表明，使用MSC治疗各种肺部疾病（包括肺气肿、支气管肺发育不良、纤维化和急性呼吸窘迫综合征）的结果很有希望。这篇小型综述将总结正在进行的使用MSC治疗肺部疾病的临床试验，严格检查支持其用于此目的的数据，并讨论MSC治疗肺部疾病的转化途径的下一步。J.细胞。115：1023-1032，2014. (c)2013 Wiley Periodicals，Inc.
All adult tissues, including the lung, have some capacity to self-repair or regenerate through the replication and differentiation of stem cells resident within these organs. While lung resident stem cells are an obvious candidate cell therapy for lung diseases, limitations exist regarding our knowledge of the biology of these cells. In contrast, there is considerable interest in the therapeutic potential of exogenous cells, particularly mesenchymal stem/stromal cells (MSCs), for lung diseases. Bone marrow derived-MSCs are the most studied cell therapy for these diseases. Preclinical studies demonstrate promising results using MSCs for diverse lung disorders, including emphysema, bronchopulmonary dysplasia, fibrosis, and acute respiratory distress syndrome. This mini-review will summarize ongoing clinical trials using MSCs in lung diseases, critically examine the data supporting their use for this purpose, and discuss the next steps in the translational pathway for MSC therapy of lung diseases. J. Cell. Biochem. 115: 1023-1032, 2014. (c) 2013 Wiley Periodicals, Inc.